BDX vs RMD vs MDLN
161 measures in 16 categories, one definition each, computed from filings and market data.
BDX42.6
Becton, Dickinson and Company
Healthcare · Medical - Instruments & Supplies
$191.75 −1.14%$52.2B mkt cap
Score DNA
RMD81.9
ResMed Inc.
Healthcare · Medical - Instruments & Supplies
$238.97 −1.35%$33.6B mkt cap
Score DNA
MDLN42.6
Medline Inc.
Healthcare · Medical - Instruments & Supplies
$35.96 −1.67%$31.5B mkt cap
Score DNA
Price, rebased to 100 three years ago
BDX RMD MDLN · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | BDX | RMD | MDLN |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 0 | 0 |
| Insider $ bought, 180d | — | — | — |
| Congress purchases, 180d | 1 | 3 | 0 |
| Last Congress purchase | 2026-09-11 | 2026-09-11 | — |
| 13F net change in holders | — | −51 | +94 |
| ETFs adding shares, 30d | 380 | 1,058 | 543 |
| ETFs trimming, 30d | 401 | 859 | 332 |
| Net ETF funds, 30d | −21 | +199 | +211 |
Valuation
16 measures| Measure | BDX | RMD | MDLN |
|---|---|---|---|
| P/E (TTM) | 55.5x
67th
|
22.1x
27th
|
85.5x
73rd
|
| PEG (P/E ÷ 3-yr EPS CAGR) | — | 1.10
43rd
|
— |
| Price / sales | 2.5x
54th
|
5.9x
79th
|
1.4x
21st
|
| Price / book | 2.1x
38th
|
5.1x
71st
|
2.7x
42nd
|
| Price / tangible book | — | 8.8x
67th
|
— |
| Price / free cash flow | 20.0x
33rd
|
11.6x
5th
|
21.2x
38th
|
| Price / operating cash flow | 15.7x
41st
|
10.6x
14th
|
23.3x
64th
|
| Enterprise value | $68.3B
96th
|
$33.0B
88th
|
$41.5B
92nd
|
| EV / sales | 3.3x
67th
|
5.8x
79th
|
1.8x
21st
|
| EV / EBITDA | 15.3x
35th
|
15.3x
30th
|
24.1x
55th
|
| EV / EBIT | 32.0x
47th
|
17.1x
18th
|
40.1x
71st
|
| EV / free cash flow | 26.2x
29th
|
11.4x
5th
|
27.8x
38th
|
| Earnings yield | 1.8%
60th
|
4.5%
84th
|
1.2%
56th
|
| FCF yield | 5.0%
72nd
|
8.6%
96th
|
4.7%
68th
|
| Operating cash flow yield | 6.4%
64th
|
9.4%
88th
|
4.3%
44th
|
| Graham number (per share) | $82.63
79th
|
$103.63
100th
|
$11.38
14th
|
Profitability (TTM)
12 measures| Measure | BDX | RMD | MDLN |
|---|---|---|---|
| Gross margin | 46.1%
32nd
|
61.2%
76th
|
25.0%
4th
|
| EBITDA margin | 21.4%
62nd
|
38.2%
96th
|
7.5%
33rd
|
| Operating margin | 9.8%
50th
|
33.5%
100th
|
5.4%
33rd
|
| EBIT margin | 10.2%
62nd
|
34.0%
100th
|
4.5%
38th
|
| Net margin | 4.5%
58th
|
26.9%
96th
|
1.6%
46th
|
| NOPAT margin | 8.0%
58th
|
26.6%
100th
|
4.1%
42nd
|
| FCF margin | 12.5%
62nd
|
51.1%
100th
|
6.5%
38th
|
| Operating cash flow margin | 16.0%
67th
|
55.8%
100th
|
5.9%
21st
|
| R&D / revenue | 5.5%
42nd
|
6.7%
58th
|
0.0%
0th
|
| SG&A / revenue | 25.3%
29th
|
19.7%
12th
|
16.6%
4th
|
| Stock comp / revenue | 1.2%
40th
|
3.2%
72nd
|
0.1%
4th
|
| Effective tax rate | 18.9%
16th
|
20.6%
32nd
|
23.8%
84th
|
Returns on capital
11 measures| Measure | BDX | RMD | MDLN |
|---|---|---|---|
| ROE (on average equity) | 3.8%
67th
|
24.3%
96th
|
3.2%
62nd
|
| ROA | 1.8%
64th
|
17.8%
100th
|
0.9%
48th
|
| ROIC | 4.1%
52nd
|
25.3%
92nd
|
4.4%
56th
|
| ROCE | 5.2%
56th
|
25.4%
96th
|
2.8%
44th
|
| Return on tangible assets | 4.0%
52nd
|
22.4%
100th
|
2.6%
44th
|
| Cash ROIC (OCF / invested capital) | 8.2%
48th
|
53.1%
100th
|
6.3%
28th
|
| Gross profitability (GP / assets) | 18.9%
28th
|
38.6%
80th
|
14.7%
12th
|
| ROIC, 3-yr average | 3.2%
57th
|
21.8%
100th
|
— |
| ROIC, 5-yr average | 3.8%
62nd
|
26.2%
100th
|
— |
| ROE, 5-yr average | 5.8%
67th
|
22.5%
100th
|
— |
| Incremental ROIC | -10.0%
29th
|
66.0%
62nd
|
— |
Growth
17 measures| Measure | BDX | RMD | MDLN |
|---|---|---|---|
| Revenue growth (TTM YoY) | -2.6%
13th
|
9.9%
57th
|
— |
| Revenue growth (QoQ) | 5.7%
56th
|
2.3%
20th
|
4.5%
48th
|
| Revenue CAGR, 3 yr | 3.0%
38th
|
10.2%
76th
|
— |
| Revenue CAGR, 5 yr | 1.2%
26th
|
12.1%
79th
|
— |
| Gross profit CAGR, 3 yr | 4.0%
62nd
|
13.6%
81st
|
— |
| Operating income CAGR, 3 yr | -3.1%
21st
|
18.7%
64th
|
— |
| Net income growth (TTM YoY) | -41.4%
0th
|
8.8%
30th
|
— |
| Net income CAGR, 3 yr | -17.3%
27th
|
19.3%
64th
|
— |
| EPS growth (TTM YoY) | -38.5%
0th
|
10.3%
30th
|
— |
| EPS CAGR, 3 yr | -16.0%
27th
|
20.0%
64th
|
— |
| EPS CAGR, 5 yr | -12.6%
45th
|
26.5%
91st
|
— |
| FCF growth (TTM YoY) | 2.2%
35th
|
74.2%
82nd
|
— |
| FCF CAGR, 3 yr | 14.4%
43rd
|
72.9%
100th
|
— |
| Operating cash flow CAGR, 3 yr | 8.2%
44th
|
65.7%
88th
|
— |
| Book value CAGR, 3 yr | -0.5%
38th
|
17.5%
100th
|
— |
| Dividend CAGR, 3 yr | 16.2%
88th
|
26.1%
100th
|
— |
| Sustainable growth rate | -3.3%
0th
|
14.5%
79th
|
3.2%
43rd
|
Margin history & stability
7 measures| Measure | BDX | RMD | MDLN |
|---|---|---|---|
| Gross margin, 3-yr average | 44.4%
27th
|
58.9%
64th
|
— |
| Operating margin, 3-yr average | 11.1%
59th
|
31.5%
100th
|
— |
| Net margin, 3-yr average | 6.4%
59th
|
25.3%
95th
|
— |
| FCF margin, 3-yr average | 13.6%
73rd
|
36.9%
100th
|
— |
| Revenue stability (0-1) | 0.53
22nd
|
1.00
100th
|
— |
| Earnings stability (0-1) | 0.78
74th
|
0.97
100th
|
— |
| Margin stability (0-1) | 0.96
41st
|
0.96
45th
|
— |
Liquidity (latest quarter)
7 measures| Measure | BDX | RMD | MDLN |
|---|---|---|---|
| Cash & short-term investments | $709.0M
76th
|
$1.5B
88th
|
$2.7B
96th
|
| Net cash (− = net debt) | −$16.1B
0th
|
$643.3M
96th
|
−$10.0B
4th
|
| Working capital | −$1.3B
0th
|
$2.9B
88th
|
$9.0B
100th
|
| Current ratio | 0.87
0th
|
3.10
64th
|
4.33
76th
|
| Quick ratio | 0.51
0th
|
2.42
64th
|
2.61
68th
|
| Cash ratio (cash + ST investments / current liabilities) | 0.08
0th
|
1.05
56th
|
0.99
52nd
|
| Defensive interval (days) | 148 days
8th
|
584 days
76th
|
508 days
72nd
|
Leverage & solvency (latest quarter)
13 measures| Measure | BDX | RMD | MDLN |
|---|---|---|---|
| Total debt | $16.8B
100th
|
$825.9M
48th
|
$12.6B
96th
|
| Debt / equity | 0.69
71st
|
0.13
25th
|
1.09
83rd
|
| Net debt / equity | 0.66
71st
|
−0.10
33rd
|
0.86
79th
|
| Debt / assets | 33.1%
72nd
|
9.2%
24th
|
32.1%
68th
|
| Debt / capital | 40.8%
71st
|
11.1%
25th
|
52.2%
83rd
|
| Debt / EBITDA | 3.77
50th
|
0.38
10th
|
7.34
85th
|
| Net debt / EBITDA | 3.61
65th
|
−0.30
25th
|
5.79
80th
|
| Interest coverage (EBIT / interest) | 3.9x
62nd
|
66.2x
95th
|
2.1x
43rd
|
| Cash interest coverage | 6.1x
57th
|
108.8x
95th
|
2.7x
24th
|
| Debt payback (years of OCF) | 5.0 yrs
45th
|
0.3 yrs
5th
|
9.3 yrs
91st
|
| Liabilities / assets | 51.9%
72nd
|
26.6%
20th
|
51.5%
68th
|
| IS credit model rating | BB+ | AAA | BB+ |
| Implied credit spread (bps) | 400
60th
|
50
0th
|
400
60th
|
Efficiency
11 measures| Measure | BDX | RMD | MDLN |
|---|---|---|---|
| Asset turnover | 0.39
28th
|
0.66
72nd
|
0.58
64th
|
| Fixed asset turnover | 3.43
44th
|
7.69
84th
|
4.86
68th
|
| Inventory turnover | 3.1
56th
|
2.3
40th
|
3.7
64th
|
| Receivables turnover | 7.9
80th
|
5.7
32nd
|
6.2
48th
|
| Days sales outstanding | 46 days
20th
|
64 days
68th
|
59 days
52nd
|
| Days inventory outstanding | 118 days
44th
|
156 days
60th
|
100 days
36th
|
| Days payables outstanding | 103 days
88th
|
49 days
40th
|
22 days
4th
|
| Cash conversion cycle (days) | 61 days
12th
|
171 days
68th
|
136 days
56th
|
| Capex / revenue | 3.5%
42nd
|
4.7%
62nd
|
— |
| Capex / depreciation | 0.31
21st
|
1.14
92nd
|
— |
| Operating expense ratio | 33.2%
25th
|
28.2%
21st
|
23.7%
8th
|
Cash flow & earnings quality
7 measures| Measure | BDX | RMD | MDLN |
|---|---|---|---|
| Operating cash flow / net income | 3.54
80th
|
2.07
60th
|
3.67
87th
|
| FCF / net income | 2.77
80th
|
1.90
60th
|
4.04
87th
|
| FCF / operating cash flow | 78.2%
62nd
|
91.5%
90th
|
— |
| Capex / operating cash flow | 21.8%
38th
|
8.5%
10th
|
— |
| Accruals ratio | -4.5%
60th
|
-19.1%
12th
|
-2.5%
88th
|
| Sloan accruals ratio | -8.4%
16th
|
2.4%
80th
|
14.5%
100th
|
| Earnings quality score (0-1) | 1.00
47th
|
0.75
13th
|
1.00
47th
|
Scores & forensic checks
15 measures| Measure | BDX | RMD | MDLN |
|---|---|---|---|
| IS score | 43
48th
|
82
100th
|
43
52nd
|
| IS profitability | 33
52nd
|
93
100th
|
16
12th
|
| IS growth | 18
0th
|
55
43rd
|
— |
| IS value | 43
52nd
|
63
92nd
|
37
16th
|
| IS momentum | 53
39th
|
81
65th
|
— |
| IS risk (safety) | 50
16th
|
100
72nd
|
50
16th
|
| IS quality | 68
60th
|
93
100th
|
55
48th
|
| IS balance sheet | 42
28th
|
91
92nd
|
39
24th
|
| IS earnings quality | 80
92nd
|
44
40th
|
79
88th
|
| IS cash flow | 59
64th
|
99
100th
|
55
56th
|
| Piotroski F-score (0-9) | 6
48th
|
7
68th
|
4
12th
|
| Altman Z-score | 2.0
28th
|
10.0
88th
|
1.9
20th
|
| Beneish M-score | −2.91
35th
|
−3.29
17th
|
— |
| Ohlson O-score | −8.24
56th
|
−12.34
4th
|
−9.12
32nd
|
| IS credit score | 46
24th
|
96
96th
|
47
36th
|
Size (TTM)
8 measures| Measure | BDX | RMD | MDLN |
|---|---|---|---|
| Market cap | $52.2B
96th
|
$33.6B
92nd
|
$31.5B
88th
|
| Revenue | $20.8B
96th
|
$5.7B
76th
|
$22.8B
100th
|
| EBITDA | $4.5B
100th
|
$2.2B
88th
|
$1.7B
84th
|
| Net income | $941.0M
88th
|
$1.5B
96th
|
$369.0M
76th
|
| Free cash flow | $2.6B
92nd
|
$2.9B
96th
|
$1.5B
88th
|
| Total assets | $50.7B
100th
|
$9.0B
68th
|
$39.4B
96th
|
| Shareholders' equity | $24.4B
100th
|
$6.6B
84th
|
$11.6B
92nd
|
| Employees | 72,000
100th
|
11,370
48th
|
45,000
96th
|
Price performance
9 measures| Measure | BDX | RMD | MDLN |
|---|---|---|---|
| 1 day | −1.1% | −1.4% | −1.7% |
| 1 week | +4.2% | +3.9% | −0.8% |
| 1 month | +5.6% | +4.6% | +12.0% |
| 3 months | +24.0% | +20.3% | −7.5% |
| 6 months | +20.8% | +4.8% | −24.5% |
| Year to date | +25.0% | −2.2% | −11.5% |
| 1 year | +3.1% | −11.2% | — |
| 3 years, cumulative | −23.5% | +69.2% | — |
| 5 years, cumulative | −11.6% | −2.3% | — |
Technicals
4 measures| Measure | BDX | RMD | MDLN |
|---|---|---|---|
| RSI 14 | 63.4 | 66.5 | 55.7 |
| From 52-week high | −5.5% | −13.7% | — |
| From 52-week low | +36.7% | +32.6% | — |
| Beta | 0.28 | 0.75 | -0.41 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17